BACKGROUND: A low CD4/CD8 ratio in human immunodeficiency virus (HIV)-infected individuals is associated with inflammation and higher risk of non-AIDS morbidity and mortality. In this study, we investigated the effect of subclinical cytomegalovirus (CMV) and Epstein-Barr virus (EBV) replication on CD4+ and CD8+ T-cell dynamics when antiretroviral therapy (ART) is started during early infection. METHODS: We investigated 604 peripheral blood mononuclear cell samples from 108 CMV- and EBV-seropositive HIV-infected men who have sex with men, who started ART within a median of 4 months from their estimated date of infection and were followed for a median of 29.1 months thereafter. Levels of CMV and EBV DNA were measured at each timepoint. Mixed-effects asymptotic regression models were applied to characterize CD4+ and CD8+ T-cell dynamics, and Bayesian hierarchical models were used to quantify individual differences in CMV and EBV DNA replication. RESULTS: Higher levels of subclinical CMV replication were associated with lower predicted maximum levels of CD4/CD8 ratio (P < .05), which was driven by higher levels of CD8+ T-cell counts (P < .05), without affecting CD4+ T-cell counts (P > .1). Age was negatively associated with CD4/CD8 levels (P < .05), and this effect was independent of the CMV association (P < .05 for both CMV and age in a multivariate model). CONCLUSIONS: Subclinical CMV replication in blood cells during early HIV infection and younger age were associated with lower CD4/CD8 ratios during suppressive ART. These findings suggest that active CMV infection in the setting of treated HIV may represent an attractive potential target for therapeutic intervention.
BACKGROUND: A low CD4/CD8 ratio in human immunodeficiency virus (HIV)-infected individuals is associated with inflammation and higher risk of non-AIDS morbidity and mortality. In this study, we investigated the effect of subclinical cytomegalovirus (CMV) and Epstein-Barr virus (EBV) replication on CD4+ and CD8+ T-cell dynamics when antiretroviral therapy (ART) is started during early infection. METHODS: We investigated 604 peripheral blood mononuclear cell samples from 108 CMV- and EBV-seropositive HIV-infectedmen who have sex with men, who started ART within a median of 4 months from their estimated date of infection and were followed for a median of 29.1 months thereafter. Levels of CMV and EBV DNA were measured at each timepoint. Mixed-effects asymptotic regression models were applied to characterize CD4+ and CD8+ T-cell dynamics, and Bayesian hierarchical models were used to quantify individual differences in CMV and EBV DNA replication. RESULTS: Higher levels of subclinical CMV replication were associated with lower predicted maximum levels of CD4/CD8 ratio (P < .05), which was driven by higher levels of CD8+ T-cell counts (P < .05), without affecting CD4+ T-cell counts (P > .1). Age was negatively associated with CD4/CD8 levels (P < .05), and this effect was independent of the CMV association (P < .05 for both CMV and age in a multivariate model). CONCLUSIONS: Subclinical CMV replication in blood cells during early HIV infection and younger age were associated with lower CD4/CD8 ratios during suppressive ART. These findings suggest that active CMV infection in the setting of treated HIV may represent an attractive potential target for therapeutic intervention.
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Lorrie Epling; Juli Teague; Mark A Jacobson; Russell P Tracy; Lawrence Corey; Steven G Deeks Journal: J Infect Dis Date: 2011-05-15 Impact factor: 5.226
Authors: M M Lederman; R McKinnis; D Kelleher; A Cutrell; J Mellors; M Neisler; E Cooney; D W Haas; R Haubrich; J Stanford; J Horton; A Landay; W Spreen Journal: AIDS Date: 2000-12-01 Impact factor: 4.177
Authors: Sulggi A Lee; Elizabeth Sinclair; Vivek Jain; Yong Huang; Lorrie Epling; Mark Van Natta; Curtis L Meinert; Jeffrey N Martin; Joseph M McCune; Steven G Deeks; Michael M Lederman; Frederick M Hecht; Peter W Hunt Journal: J Infect Dis Date: 2014-02-28 Impact factor: 5.226
Authors: Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman Journal: J Virol Date: 2008-03-19 Impact factor: 5.103
Authors: D C Douek; R D McFarland; P H Keiser; E A Gage; J M Massey; B F Haynes; M A Polis; A T Haase; M B Feinberg; J L Sullivan; B D Jamieson; J A Zack; L J Picker; R A Koup Journal: Nature Date: 1998-12-17 Impact factor: 49.962
Authors: Sara Gianella; Christy M Anderson; Susanna R Var; Michelli F Oliveira; Steven M Lada; Milenka V Vargas; Marta Massanella; Susan J Little; Douglas D Richman; Matthew C Strain; Josué Pérez-Santiago; Davey M Smith Journal: J Virol Date: 2016-03-28 Impact factor: 5.103
Authors: Sergio Serrano-Villar; Talia Sainz; Sulggi A Lee; Peter W Hunt; Elizabeth Sinclair; Barbara L Shacklett; April L Ferre; Timothy L Hayes; Ma Somsouk; Priscilla Y Hsue; Mark L Van Natta; Curtis L Meinert; Michael M Lederman; Hiroyu Hatano; Vivek Jain; Yong Huang; Frederick M Hecht; Jeffrey N Martin; Joseph M McCune; Santiago Moreno; Steven G Deeks Journal: PLoS Pathog Date: 2014-05-15 Impact factor: 6.823
Authors: Aaron Christensen-Quick; Christophe Vanpouille; Andrea Lisco; Sara Gianella Journal: AIDS Res Hum Retroviruses Date: 2017-11 Impact factor: 2.205
Authors: Eshan U Patel; Sara Gianella; Kevin Newell; Aaron A R Tobian; Allison R Kirkpatrick; Fredrick Nalugoda; Mary K Grabowski; Ronald H Gray; David Serwadda; Thomas C Quinn; Andrew D Redd; Steven J Reynolds Journal: AIDS Date: 2017-03-27 Impact factor: 4.177
Authors: Jennifer A Manuzak; Toni M Gott; Jay S Kirkwood; Ernesto Coronado; Tiffany Hensley-McBain; Charlene Miller; Ryan K Cheu; Ann C Collier; Nicholas T Funderburg; Jeffery N Martin; Michael C Wu; Nina Isoherranen; Peter W Hunt; Nichole R Klatt Journal: Clin Infect Dis Date: 2018-06-01 Impact factor: 20.999